Objectives Despite clozapine's superior clinical efficacy in Treatment Resistant
Schizophrenia (TRS), its adverse effects, need for periodic leukocyte monitoring, cost and …

Although clozapine is the main antipsychotic medication for treatment-resistant
schizophrenia, 40–70% of patients on clozapine have persistent psychotic symptoms (ie …

Clozapine has been identified as the drug of choice in refractory or treatment-resistant
schizophrenia; however, as many as 40–70% of individuals continue to demonstrate …

Introduction Treatment resistant schizophrenia (TRS), affecting approximately one-third of
patients with schizophrenia, is associated with a serious impairment in global psychosocial …

BACKGROUND: Several lines of evidence suggest that clozapine is more effective than both
first-and second-generation antipsychotic drugs in treatment-resistant schizophrenia (TRS) …

Purpose/Background: The favorable effect of clozapine on psychotic symptoms in patients
with treatment-resistant (TR) schizophrenia (SCZ) in short-term studies is well established …

Background It is unknown whether increasing the clozapine plasma level to 400, 750, or
even 1000 ng/mL is a feasible and effective strategy in patients with treatment-resistant …

Background: Clozapine is the only medication licenced for treating patients with treatment-
refractory schizophrenia. However, there are no evidence-based guidelines as to the …

Randomized clinical trials have limitations because they focus on small samples of highly
selected patients. Observational studies, which follow large cohorts of typical patients …

Japan approved clozapine for treatment-resistant schizophrenia in June 2009. The aim of
this study was to evaluate clozapine's efficacy and tolerability in Japanese patients. A twelve …